Abstract |
The measure of glycated hemoglobin (HbA1c) concentration is the gold standard of glycemic control index in diabetes management and is well known as a marker for diabetes complications. However, HbA1c level neither accurately reflect glucose fluctuations, nor does it provide a clear indication of glycemic control in recent days or weeks. HbA1c concentration measurement can be confounded in patients with anemia, hemoglobinopathy, liver disease, or renal impairment. 1,5-Anhydroglucitol (1,5-AG) structurally resembles glucose. It can be influenced by diet or medication, gender and race, especially severe renal disease and various pathological conditions. Most notably, 1,5-AG level is reflective of short-term glucose status, postprandial hyperglycemia, and glycemic variability which are not captured by HbA1c assay. 1,5-AG may suggest an alternative index of subtypes of diabetes and a warning sign of diabetes complications. This review provides an overview of our current understanding of the role of 1,5-AG marker in diabetes. However, further investigations on the associations between this glycemic marker and diabetes complications are needed.
|
Authors | Won Jun Kim, Cheol-Young Park |
Journal | Endocrine
(Endocrine)
Vol. 43
Issue 1
Pg. 33-40
(Feb 2013)
ISSN: 1559-0100 [Electronic] United States |
PMID | 22847316
(Publication Type: Journal Article, Review)
|
Chemical References |
- 2,5-anhydroglucitol
- Biomarkers
- Deoxyglucose
|
Topics |
- Animals
- Biomarkers
(blood, metabolism)
- Deoxyglucose
(analogs & derivatives, blood, metabolism)
- Diabetes Mellitus, Type 1
(blood, complications, metabolism, therapy)
- Diabetes Mellitus, Type 2
(blood, complications, metabolism, therapy)
- Diabetic Angiopathies
(prevention & control)
- Diabetic Nephropathies
(prevention & control)
- Humans
- Hyperglycemia
(prevention & control)
- Kidney
(metabolism)
- Postprandial Period
|